Feb 23, 2026 Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
Nov 6, 2025 Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
